TWiV 845: COVID-19 clinical update #94 with Dr. Daniel Griffin
About this episode
In COVID-19 clinical update #94, Daniel Griffin reviews the FDA EUA for Paxlovid, test to stay in school, immunity after infection, variants and therapeutics, quarantine and isolation guidelines, Molnupiravir in non-hospitalized patients, and convalescent serum in outpatients.
Subscribe (free): iTunes, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- FDA EUA for Paxlovid (pdf)
- Children and COVID-19 (pdf)
- Evaluation of test to stay in school, IL (MMWR)
- Evaluation of test to stay in school, LA (MMWR)
- Update on mRNA vaccine in under 5 yo (Pfizer)
- CDC endorses preference for mRNA vaccines (CDC)
- Natural immunity and protection against delta (Clin Inf Dis)
- Cross-neutralization post-vaccination infection (JAMA)
- Variants and therapeutics (NIH)
- Quarantine and isolation (CDC)
- Molnupiravir in non-hospitalized patients (NEJM)
- Convalescent serum for outpatients (medRxiv)
- Letters read on TWiV 845
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkee
Send your questions for Dr. Griffin to [email protected]
Get every episode summarized
Each time This Week in Virology publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from This Week in Virology
TWiV 1309: Maybe they're all cancer vaccines
This Week in Virology
TWiV 1308: Clinical update with Dr. Daniel Griffin
This Week in Virology
TWiV 1307: My heart breaks for flu
This Week in Virology
TWiV 1306: Clinical update with Dr. Daniel Griffin
This Week in Virology